Gege Gui

I’m so proud of @Meg_Goswami and @GegeGui0 for this work. While this was only a small clinical trial they have shown with their strong logic and beautiful science that in AML patients there was no evidence that adding anti-PD1 treatment to HMA resulted in additional benefit.

New preprint from houriganlab.com @TheBethesdaLabs We are obsessed with MEASURABLE residual disease in AML, the idea that with higher sensitivity tools we can get better sense of leukemic burden and relapse risk for individuals in “remission”.

New results from the @BMT_CTN 0901 trial and @TheBethesdaLabs @nih_nhlbi: The Impact Of Conditioning Intensity And Genomics On Relapse After Allogeneic Transplantation For Patients W/ Myelodysplastic Syndrome fal.cn/3dAoo #jcopo